Saphnelo recommended for approval in EU by CHMP for treatment of patients with systemic lupus erythematosus

AstraZeneca’s Saphnelo (anifrolumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy for the

Related Keywords

Canada ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Manchester ,Ian Bruce ,Astrazeneca Saphnelo ,Medarex Inc ,University Of Manchester ,Nasdaq ,Company On Twitter Astrazeneca ,Astrazeneca ,European Union ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Executive Vice President ,Bristol Myers Squibb ,Uncontrolled Lupus ,Interferon Pathway ,Based Composite Lupus Assessment ,New England Journal ,Lancet Rheumatology ,Rare Diseases ,